ReviewNature reviews. Rheumatology2019
The IL-23-IL-17 pathway as a therapeutic target in axial spondyloarthritis.
Review in Nature reviews. Rheumatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed, 2 syntheses or guidelines pooled it, 136 citations in OpenAlex.
- Upadacitinib for axial spondyloarthritis: a meta-analysis of efficacy and safety.Clinical rheumatology · 2024Pooled it
- Comparative efficacy and safety of bimekizumab in axial spondyloarthritis: a systematic literature review and network meta-analysis.Rheumatology (Oxford, England) · 2024Pooled it
- Trial
- Trial
- Article
- Methotrexate's effect on cells and adalimumab immunogenicity in axial spondyloarthritis: A mathematical study.PLoS computational biology · 2026Article
- Pro-Inflammatory Synergy Between IL-17, IL-1 and Hyperuricemia in Psoriatic Arthritis: Clinical Implications of a Pilot Study.Diseases (Basel, Switzerland) · 2026Article
- Vunakizumab for IL-17A-Mediated Diseases: A Review in Psoriasis and Spondyloarthritis.Biologics : targets & therapy · 2026Review
- Nrf2 as a redox checkpoint in autoimmune joint inflammation: microenvironmental redox control across the arthritis spectrum.Frontiers in immunology · 2026Review
- Lentinula edodes Cultured Extract Intake at Puberty Mitigates Inflammatory Signals at the Mammary Glands by the Involvement of Epigenetic Mechanisms in BALB/c Mice.The breast journal · 2026Article
- Elevated serum interleukin-41 levels as a potential biomarker in ankylosing spondylitis.Future science OA · 2025Article
- New Insight into Bone Immunity in Marrow Cavity and Cancellous Bone Microenvironments and Their Regulation.Biomedicines · 2025Review
- Serum Levels of 54 Cytokines and Chemokines Reveal Distinct Inflammatory Signatures in Ankylosing Spondylitis.Immunity, inflammation and disease · 2025Article
- Comprehensive Profiling of Cytokines and Growth Factors: Pathogenic Roles and Clinical Applications in Autoimmune Diseases.International journal of molecular sciences · 2025Review
- Chicken IL-17 as a potent adjuvant enhances IBDV VP2 DNA vaccine immunogenicity and protective efficacy.Poultry science · 2025Article
- The Role of Diet in Modulating Inflammation and Oxidative Stress in Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis.Nutrients · 2025Review
- The Role of IL-17 in Systemic Autoinflammatory Diseases: Mechanisms and Therapeutic Perspectives.Clinical reviews in allergy & immunology · 2025Review
- RORγt inverse agonists demonstrating a margin between inhibition of IL-17A and thymocyte apoptosis.PloS one · 2025Article
- HLX and SLC25A20: Immunologic regulators bridging ankylosing spondylitis and uveitis via multi-omics integration and machine learning.PloS one · 2025Article
- Targeting fibroblasts in pathological bone formation: mechanisms and treatments.Frontiers in cell and developmental biology · 2025Review
15 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The cytokines IL-23 and IL-17 have an important role in the pathogenesis of, and as a therapeutic target in, both animal models of chronic inflammation and some human chronic inflammatory diseases. The traditional view is that a main source of IL-17 is T cells and that IL-17 production is under the control of IL-23. IL-17 inhibition has shown good efficacy in clinical trials for ankylosing spondylitis (AS), a subtype of axial spondyloarthritis (axSpA) characterized by radiographic evidence of sacroiliitis. On the basis of data from animal models, genetic studies and the investigation of tissue and blood samples from patients with AS, IL-23 had also been predicted to be important in the pathogenesis of this disease and was therefore considered a potential therapeutic target for axSpA. However, two placebo-controlled, double-blind clinical trials in axSpA of monoclonal antibodies directed against either the p40 protein or the p19 protein of the IL-23 molecule had clear negative results. These findings indicate that IL-23 and IL-17 are at least partly uncoupled in axSpA. Reasons as to why, when and how such an uncoupling might occur are discussed in this Review, with special reference to the unique microenvironment of the subchondral bone marrow in axSpA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.